Adaptive Phage Therapeutics Announces “The AMR RAPID™ Challenge”
APT's phage bank, in combination with our Phage Susceptibility Test (PST), closes the loop in antibiotic development, breaking the failed cycle of repeated antibiotic product introduction followed by resistance-driven obsolescence. Unlike traditional antibiotic development, APT's phage bank approach is designed to adapt to emerging resistance within weeks. With the combination of the world's largest and most diverse therapeutic phage collection and the integration of real-time surveillance of phage susceptibility, gaps in antibiotic spectrum are now guaranteed to be covered by APT's phage bank.
AMR bacteria are no match for APT’s phage bank. We guarantee it.
With APT's AMR RAPID Challenge we will pay $1,000 to any individual or institution that identifies a bacteria within the CDC's most serious and urgent biological threat categories (i.e. the "ESKAPE" pathogens*) that APT does not cover with its phage bank (see rules and conditions below). We especially welcome bacterial isolates that are completely resistant to all available antibiotics.
* ESKAPE = Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter